Lipid Nanoparticle (mRNA delivery)
A 100-nanometer fat bubble that taught a billion immune systems to recognize a virus.
Lipid nanoparticles (LNPs) are ~100 nm spherical assemblies of four lipid components — an ionizable cationic lipid, a phospholipid, cholesterol, and a PEGylated lipid — that encapsulate mRNA at >90 % efficiency. After intramuscular injection, LNPs are taken up by local muscle and antigen-presenting cells via endocytosis. The ionizable lipid, neutral at physiological pH, becomes positively charged in the endosome (pH ~5–6), destabilizes the endosomal membrane, and releases mRNA into the cytoplasm where ribosomes translate it into protein. For the SARS-CoV-2 vaccines (Pfizer-BioNTech BNT162b2; Moderna mRNA-1273), the encoded protein is a stabilized spike antigen.
LNPs are produced by rapid microfluidic mixing: an ethanol stream containing the four lipids meets an aqueous stream containing mRNA at low pH, on millisecond timescales, in a chip mixer. The pH gradient drives the ionizable lipid to a positively charged form that electrostatically condenses with the negatively charged mRNA backbone; cholesterol provides membrane fluidity; the phospholipid (DSPC or similar) forms the outer shell; PEG-lipid (~1.5 mol %) caps the surface, shielding from serum protein adsorption and limiting particle aggregation. The mixed dispersion is then dialyzed to neutral pH, at which the ionizable lipid becomes neutral and the mRNA is locked inside. After IM injection, LNPs distribute predominantly to the injection-site muscle and the draining lymph node, with smaller amounts reaching the liver — biodistribution measurements with luciferase-mRNA LNPs show >99 % of payload localized to muscle and liver within 24 hours, with rapid clearance over days. The ionizable-lipid pKa (~6.4) is the primary determinant of endosomal escape efficiency: too high and LNPs aggregate in serum, too low and they fail to disrupt the endosome. Acuitas's ALC-0315 (Pfizer) and Moderna's SM-102 are the dominant clinical ionizable lipids.
In plain terms
Imagine you wrote a recipe on a piece of tissue paper. If you tried to mail it, rain would dissolve it in seconds. So you fold it into an oily soap bubble that survives the trip, sneaks inside the kitchen, and pops open right next to the cook. The cook reads the recipe once, makes the dish, then throws away both the recipe and the bubble. Lipid nanoparticles do the same with mRNA: they keep the message intact through the bloodstream and into a cell, then dissolve so the cell's machinery can read the recipe and build the right protein.
Also called: LNP, mRNA-LNP, ionizable lipid nanoparticle.
Why it matters
- Made the first widely deployed mRNA vaccines possible — over 5 billion COVID-19 mRNA-LNP doses administered globally by 2024.
- Generalizable platform: changing only the encapsulated mRNA produces vaccines or therapies for new pathogens or genetic diseases without redesigning the carrier.
- Validated in clinic: Onpattro (patisiran, Alnylam, 2018) was the first FDA-approved siRNA-LNP, treating hereditary transthyretin amyloidosis.
- Active R&D toward tissue-targeted LNPs (lung, CNS, hematopoietic stem cells) for gene editing and protein-replacement therapies.
Where it lives
- Pfizer-BioNTech Comirnaty (BNT162b2) — ALC-0315 ionizable lipid
- Moderna Spikevax (mRNA-1273) — SM-102 ionizable lipid
- Onpattro (patisiran) siRNA-LNP for hATTR amyloidosis
- Acuitas / Genevant / Arcturus LNP platforms
Key numbers
- Particle diameter: ~80–120 nm
- mRNA encapsulation: >90 % (Standard for clinical formulations)
- Ionizable-lipid pKa: ~6.4 (Tuned for endosomal escape)
- Doses delivered (COVID-19, by 2024): >5 billion
- First FDA-approved LNP: Onpattro (patisiran) (siRNA, 2018)
Surprising facts
- The four-lipid formulation in BNT162b2 self-assembles into ~80 nm particles by mixing two solvent streams in a microfluidic chip in less than a millisecond — no proteins or specialized machinery are needed.
- A single 30 µg dose of Pfizer-BioNTech vaccine contains ~10¹³ LNPs, each encapsulating roughly one to a few mRNA copies — enough recipes to brief many millions of cells in the deltoid muscle.
- The ionizable cationic-lipid trick (neutral at pH 7.4, positive at pH 5) was developed by Pieter Cullis and coworkers in Vancouver in the 2000s and is the single most important enabler of in-vivo mRNA delivery.
Open questions
- Biodistribution claims are widely misrepresented: A 2021 Japanese regulatory document (a Pfizer-BioNTech rat biodistribution study summary) is frequently cited online as showing LNPs 'accumulate in ovaries.' The actual study reports that in luciferase-mRNA rodent biodistribution, ~99 % of injected dose stays at the muscle injection site or moves to liver/spleen, with sub-percent levels detected transiently in many other tissues including ovaries and adrenals — a normal finding for any IM-injected lipid formulation. Clinical safety reviews by FDA, EMA, MHRA, and national regulators have all concluded the rodent biodistribution does not indicate ovarian accumulation in humans. This is a frequently miscited document.
- Myocarditis signal in young males: Surveillance after rollout identified a real, well-documented increased rate of myocarditis after mRNA vaccination, especially in males aged 16–29 after the second dose, at rates of roughly 1 in 5,000 to 1 in 30,000 depending on age. Cases were predominantly mild and self-limiting; CDC, EMA, and ATAGI updated dosing guidance in response. The mechanism is not fully established and remains a subject of cardiology research.
A short history
Pieter Cullis and colleagues (Vancouver, late 1990s and 2000s) developed the ionizable-lipid concept that distinguishes modern LNPs from conventional cationic liposomes. Acuitas Therapeutics, Arbutus, Genevant, and Alnylam refined formulations through siRNA work that culminated in Onpattro (2018). When BioNTech and Moderna designed COVID-19 mRNA vaccines in 2020, both used LNP carriers — Pfizer-BioNTech with Acuitas's ALC-0315, Moderna with its in-house SM-102. Phase 3 efficacy results in late 2020 (~95 %) and emergency use authorization in December 2020 made LNPs the most clinically deployed nanomedicine in history within months.
Sources
- Hou et al., Nature Reviews Materials (2021) — Lipid nanoparticles for mRNA delivery (https://www.nature.com/articles/s41578-021-00358-0)
- Polack et al., NEJM (2020) — BNT162b2 efficacy (https://www.nejm.org/doi/full/10.1056/NEJMoa2034577)
- Adams et al., NEJM (2018) — Patisiran trial (https://www.nejm.org/doi/full/10.1056/NEJMoa1716153)
- Cullis & Hope, Mol. Ther. (2017) — Lipid nanoparticle systems (https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(17)30184-6)